Company Monitoring Page for Reata-Pharmaceuticals

latest headlines for company on cafepharma

Biogen lays off staffers at newly acquired Reata, with 113 set to lose positions
Fierce Pharma
Wed, 10/11/23 - 11:55 pm
Tags:
Biogens, layoffs, Reata Pharmaceuticals
How Biogen outbid a rival 'large-cap' pharma to claim Reata for $7.3B
Fierce Pharma
Tue, 08/15/23 - 11:53 am
Tags:
Biogen, Reata Pharmaceuticals, M&A, Skyclarys, Friedreich’s ataxia
Could This $6.5 Billion Acquisition Help Turn Biogen's Business Around?
Motley Fool
Thu, 08/10/23 - 09:57 am
Tags:
Biogen, Reata Pharmaceuticals, M&A, Skyclarys
Biogen's Just Made Its Biggest Acquisition. Here's What You Need to Know.
Motley Fool
Tue, 08/1/23 - 11:55 am
Tags:
Biogen, Reata Pharmaceuticals, M&A
Biogen to acquire rare disease drugmaker Reata for $7.3B
BioPharma Dive
Fri, 07/28/23 - 11:50 am
Tags:
Biogen, Reata Pharmaceuticals, M&A, Friedreich's Ataxia
Biopharma stocks go back to bleak
EP Vantage
Thu, 04/6/23 - 09:51 am
Tags:
Albireo Pharma, Amryt Pharma, Apellis Pharmaceuticals, AstraZeneca, BridgeBio, Novo Nordisk, Pfizer, Protagonist Therapeutics, Provention Bio, Reata Pharmaceuticals, Regeneron, Sanofi, Seagen
FDA Approves First Therapy for Friedreich's Ataxia
BioSpace
Tue, 02/28/23 - 10:48 pm
Tags:
Reata Pharmaceuticals, FDA, Friedreich's Ataxia
FDA scraps AdComm for Reata's rare disease candidate, leaving analysts squinting at the tea leaves
Fierce Biotech
Sun, 10/16/22 - 05:17 pm
Tags:
Reata Pharmaceuticals, omaveloxolone, FDA, Friedreich's Ataxia
Reata’s ‘regulatory concerns’ turn into three-month delay on FDA decision for Friedreich’s ataxia drug
Endpoints
Tue, 08/9/22 - 10:27 am
Tags:
Reata Pharmaceuticals, Friedreich's Ataxia, FDA, omaveloxolone
FDA regulatory roundup: two approvals, three rejections & one clinical hold
MedCity News
Sun, 03/6/22 - 11:08 pm
Tags:
FDA, JNJ, CTI BioPharma, Gilead Sciences, Amryt Pharma, Reata Pharmaceuticals
FDA rejects Reata Pharma chronic kidney disease drug; new trial needed
MedCity News
Mon, 02/28/22 - 09:15 am
Tags:
Reata Pharmaceuticals, Bardoxolone, Alport syndrome, kidney disease, FDA
FDA adcomm votes unanimously against Reata's potential Alport syndrome treatment
Endpoints
Wed, 12/8/21 - 11:41 pm
Tags:
FDA, Reata Pharmaceuticals, Alport syndrome
Reata Pharmaceuticals Sees Hiccup in Filing for Approval of FA Drug
BioSpace
Wed, 08/12/20 - 12:11 am
Tags:
Reata Pharmaceuticals, Friedreich's Ataxia, omaveloxolone
Reata Bags $350M As It Preps Rare Chronic Kidney Disease Drug For FDA
Xconomy
Thu, 06/11/20 - 10:42 pm
Tags:
Reata Pharmaceuticals, kidney disease, Alport, chronic kidney disease, bardoxolone methyl
Reata Pharmaceuticals Says Ongoing Trials In Patients With Pulmonary Arterial Hypertension Stopped Due To High Risk Of COVID-19 To These Patients
Reuters
Mon, 03/30/20 - 08:18 pm
Tags:
Reata Pharmaceuticals, PAH, clinical trials, COVID-19
Reata Pharmaceuticals Just Raised $505 Million to Treat Orphan Diseases
Motley Fool
Tue, 11/26/19 - 10:29 am
Tags:
Reata Pharmaceuticals, orphan diseases, omaveloxolone
Reata's bardoxolone offers promise in patients with rare kidney disorder
Endpoints
Tue, 11/12/19 - 10:22 am
Tags:
Reata Pharmaceuticals, Bardoxolone, chronic kidney disease, Alport syndrome
Reata shocks analysts with pivotal win in Friedreich's ataxia
Fierce Biotech
Tue, 10/15/19 - 10:18 am
Tags:
Reata Pharmaceuticals, omaveloxolone, Friedreich's Ataxia, clinical trials
AbbVie Stays Busy While Working to Complete Allergan Acquisition
BioSpace
Fri, 10/11/19 - 10:34 pm
Tags:
AbbVie, Allergan, M&A, Skyrizi, Reata Pharmaceuticals
Reata buys drug rights back from AbbVie for $330M before readout
Biopharma Dive
Thu, 10/10/19 - 12:53 pm
Tags:
Reata Pharmaceuticals, AbbVie, bardoxolone methyl

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.